Lund University Cancer Center Distinguished Seminar

4 Oct '16
16:00 - 17:00
The Auditorium (Hörsalen), Medicon Village
Lund University Cancer Center@Medicon Village

Peter Blume-Jensen, MD, PhD, CSO XTuit Pharmaceuticals, Inc. Waltham, MA, US

Lund University Cancer Center Distinguished Seminar
“Microenvironment-targeted therapeutics and drug-tailored biomarkers for patient response prediction”

Time and location: Tuesday October 4 at 16.00, Medicon Village, Inspira Lower Dining Hall (Nedre Matsalen), Scheelevägen 2, Lund . Contact:

Dr. Peter Blume-Jensen has extensive expertise in basic and translational cancer research, oncogenic signaling, targeted therapeutic drug discovery, and stratified clinical trial design. He has worked in the pharma industry for more than twenty years. In 2010 he joined Metamark Genetics as CSO, where he built R&D, a novel, automated proteomics imaging platform for CLIA-certified cancer tests. He designed and led 4 clinical studies culminating with the successful, blinded, clinical validation of ProMark™, a prognostic prostate cancer biopsy test, now included under NCCN guidelines and Medicare/Medicaid coverage. Since June, 2014 Peter has joined XTuit, an oncology and fibrosis therapeutics company, as CSO and first employee. Here he is leading R&D and an integrated early clinical strategy and trial design based on his invention for drug-tailored efficacy prediction.

Blume-Jensen obtained his M.D. from Copenhagen, Denmark, his Ph.D. from Dr. Carl-Henrik Heldin’s lab at the Ludwig Institute for Cancer Research, Uppsala, Sweden, and conducted his Post-­‐Doctoral studies in Dr. Tony Hunter’s laboratory at the Salk Institute, La Jolla, CA. He has consulted extensively for Biotech and Pharma on targeted therapeutics and Precision Medicine.

Selected publications:

Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH; Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P and Paweletz CF (2010) Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med. 2, 43ra55

Swami, M. (2010) A discovery strategy for novel cancer biomarkers. Nature Rev Cancer 10, 597 (commentary on Andersen et al. 2010)

Solit DB andMellinghoff IK. (2010)Tracing cancer networks with phosphoproteomics. Nat Biotech  10, 1028-1029 (commentary on Andersen et al., 2010)

Shipitsin M, Small C, Choudhury S, Giladi E, Friedlander S, Nardone J, Hussain S, Hurley AD, Ernst C, Huang YE, Chang H, Nifong TP, Rimm DL, Dunyak J, Loda M, Berman DM and Blume-Jensen P (2014) Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. Br. J. Cancer 111, 1201-12

Blume-Jensen P, Berman DM, Rimm DL, Shipitsin M, Putzi M, Nifong TP, Small C, Choudhury S, Capela T, Coupal L, Ernst C, Hurley A, Kaprelyants A, Chang H, Giladi E , Nardone J, Dunyak J, Loda M, Klein EA, Magi-Galluzzi C, Latour M, Epstein JI, Kantoff P, Saad F (2015) Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer. Clin Cancer Res 21, 2591-600